Search for content, post, videos
Advertisement

Alligator Bioscience announces IND approval

Søren Bregenholt

Shanghai Henlius Biotech has received IND approval from China’s National Medical Products Administration for a Phase 2 clinical trial of AC101 in combination with anti-PD-1 monoclonal antibody HANSIZHUANG, HANQUYOU and chemotherapy as a 1st line treatment for HER2-positive locally advanced/metastatic gastric cancer patients.

Alligator out-licensed AC101 (HLX22) to the South Korean company AbClon, Inc. in 2016, who sub-licensed the drug candidate to Henlius Biotech for clinical and commercial development in China. Alligator retains an ownership interest entitling the company to 35% of AbClon’s income from the agreement with Henlius.
In September 2022, Henlius announced the completion of the Phase 1 trial of AC101 (HLX22) in patients with HER2 overexpressing advanced solid tumors, in which it demonstrated a good safety and tolerability profile.

“It is a further boost to the potential of our AC101 (HLX22) asset, and we are particularly looking forward to seeing what results this new combination setting yields, especially as it includes the addition of the anti-PD-1 monoclonal antibody serplulimab.”

“Henlius is making very encouraging progress in its clinical development of AC101 (HLX22) in gastric cancer,” says Søren Bregenholt, CEO of Alligator Bioscience. “Following the good safety and tolerability results from the Phase 1 study in September, this is now the second Phase 2 study the company has initiated with this candidate in this indication. It is a further boost to the potential of our AC101 (HLX22) asset, and we are particularly looking forward to seeing what results this new combination setting yields, especially as it includes the addition of the anti-PD-1 monoclonal antibody serplulimab.”

Advertisement

Completion date is expected in September 2024

Henlius initiated a prior Phase 2 clinical trial to evaluate AC101 (HLX22) in combination with HANQUYOU (trastuzumab) and chemotherapy as a first-line treatment for HER2-positive locally advanced/metastatic gastric cancer patients in September 2021. The estimated primary completion date is April 2023, and the study completion date is expected in September 2024.

Photo of Søren Bregenholt

Advertisement